300 results found.

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.
fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO).
IPI-145; Ofatumumab

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large Clinical Trial using GS-9973

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies.
GS-9973

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07.
IPI-145; Ofatumumab

Hematopoietic/Lymphoid Cancer, Non-hodgkin Lymphoma,B Cell, or Re Clinical Trial using Biological: anti-CD19-CAR vector-transduced T cells genetically engineered lymphocyte therapy

Chinese PLA General Hospital - Recruiting 50 years to 80 years.
- Anti-CD19 Chimeric Antigen Receptor Modified T Cells Infusion in Mantle Cell Lymphoma.
Biological: anti-CD19-CAR vector-transduced T cells genetically engineered lymphocyte therapy

Lymphoma, Follicular Clinical Trial using BI 695500; MabThera

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular Lymphoma.
BI 695500; MabThera

Lymphoma, Non-Hodgkin Clinical Trial using BI 836826

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin.
BI 836826

Lymphoma Clinical Trial using Bendamustine; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; PCI-32765 (Ibrutinib); Placebo

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL).
Bendamustine; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; PCI-32765 (Ibrutinib); Placebo

Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymph Clinical Trial using Idelalisib

Gilead Sciences - Recruiting 18 years or older.
- Single-agent CAL-101 for Previously Teated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events.
Idelalisib

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkins Lymphoma.
veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

Leukemia, or Lymphoma Clinical Trial using Rasburicase; Allopurinol

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Randomized Phase 2 Study to Evaluate the Efficacy of Rasburicase in Patients at Risk for TLS During Two Cycles of Chemotherapy.
Rasburicase; Allopurinol

B-cell Childhood Acute Lymphoblastic Leukemia, Peripheral T-cell Clinical Trial using dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase 1 Study of Temsirolimus in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.
dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

Carcinoma, or Lymphoma Clinical Trial using rh IL-15

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers.
rh IL-15

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lym Clinical Trial using CPX-351

Children's Hospital Medical Center, Cincinnati - Recruiting 12 Months to 30 years.
- A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies.
CPX-351

Non-Hodgkin's Lymphoma Clinical Trial using bendamustine; RO5072759

Genentech - Recruiting 18 years or older.
- An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma.
bendamustine; RO5072759

Lymphocytic Leukemia, Chronic, Lymphoma, B-Cell Clinical Trial using GDC-0853

Genentech - Recruiting 18 years or older.
- AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA.
GDC-0853

Non-Hodgkin's Lymphoma, Solid Cancers Clinical Trial using GDC-0980

Genentech - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors and Non-Hodgkin's Lymphoma.
GDC-0980

Lymphoma, B-Cell, Non-Hodgkin's Lymphoma Clinical Trial using DCDS4501A; rituximab [MabThera/Rituxan]; cyclophosphamide; prednisone; doxorubicin

Genentech - Recruiting 60 years to 80 years.
- A PHASE Ib STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF DCDS4501A IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA.
DCDS4501A; rituximab [MabThera/Rituxan]; cyclophosphamide; prednisone; doxorubicin

Lymphoma, Solid Tumour Clinical Trial using GDC-0575; gemcitabine

Genentech - Recruiting 18 years or older.
- An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma.
GDC-0575; gemcitabine

Lymphoma Clinical Trial using PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma.
PCI-32765 (Ibrutinib)

Diffuse Large B-cell Lymphoma, or Follicle Center Lymphoma Clinical Trial using Zevalin (ibritumomab tiuxetan)

Spectrum Pharmaceuticals, Inc - Recruiting 60 years or older.
- A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy.
Zevalin (ibritumomab tiuxetan)

Hodgkin's Lymphoma Clinical Trial using Panobinostat; Ifosfamide; Mesna; Carboplatin; Etoposide; Pegfilgrastim

M.D. Anderson Cancer Center - Recruiting 16 years or older.
- Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by a Randomized Phase-II Study of ICE Compared With Panobinostat Plus ICE for Patients With Relapsed and Refractory Classical Hodgkin Lymphoma.
Panobinostat; Ifosfamide; Mesna; Carboplatin; Etoposide; Pegfilgrastim

T-cell Lymphomas, T-cell Leukemia, Sezary Syndrome, Mycosis Fungo Clinical Trial using A-dmDT390-bisFv(UCHT1)

Angimmune LLC - Recruiting 18 years or older.
- A Phase I/II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Surface CD3+ Malignant T Cell Diseases.
A-dmDT390-bisFv(UCHT1)

Leukemia, Lymphoma, or Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using busulfan; cyclophosphamide; Stem cell infusion; Total body irradiation

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia.
busulfan; cyclophosphamide; Stem cell infusion; Total body irradiation

Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Ly Clinical Trial using Dasatinib

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies..
Dasatinib

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Mul Clinical Trial using Dasatinib; laboratory biomarker analysis

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies..
Dasatinib; laboratory biomarker analysis

Advanced Cancer, Metastatic Cancer, Lymphoma, Metastatic Breast C Clinical Trial using LY3023414; Midazolam; Letrozole

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer.
LY3023414; Midazolam; Letrozole

Osteonecrosis, Acute Lymphoblastic Leukaemia, or Lymphoblastic Ly Clinical Trial

Heinrich-Heine University, Duesseldorf - Recruiting 10 years to 18 years.
- Part I: Incidence, Clinical Course and Significance of MRI for Early Diagnosis of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Part II: Susceptibility for Aseptic Osteonecroses in Children and Adolescents With Chemotherapy for ALL or LBL.

CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Lo Clinical Trial using Everolimus and Rituximab

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas and Hodgkin's Lymphoma.
Everolimus and Rituximab

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

Lymphoma Clinical Trial using Ofatumumab; Ifosfamide; Etoposide; Mesna; G-CSF; Stem Cell Collection

M.D. Anderson Cancer Center - Recruiting 18 years to 70 years.
- Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas.
Ofatumumab; Ifosfamide; Etoposide; Mesna; G-CSF; Stem Cell Collection

Peripheral T-Cell Lymphoma, or Diffuse Large B-Cell Lymphoma Clinical Trial using Gemcitabine; Dexamethasone; Cisplatin; Romidepsin

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma.
Gemcitabine; Dexamethasone; Cisplatin; Romidepsin

Lymphoma, Non-Hodgkin Clinical Trial using Copanlisib (BAY80-6946)

Bayer - Recruiting 18 years or older.
- Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas.
Copanlisib (BAY80-6946)

Mantle Cell Lymphoma Clinical Trial using LY2835219

Eli Lilly and Company - Recruiting 18 years or older.
- Phase 2 Study of a CDK4/6 Inhibitor for Patients With Relapsed or Refractory Mantle Cell Lymphoma.
LY2835219

Hepatosplenic T-Cell Lymphoma Clinical Trial using Collection of samples

Janssen Scientific Affairs, LLC - Recruiting N/A or older.
- A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL).
Collection of samples

Lymphoma Clinical Trial using CPI-0610

Constellation Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma.
CPI-0610

Lymphoma, Non-Hodgkin Clinical Trial using Rituximab; Lenalidomide; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma (The 'AUGMENT' Study).
Rituximab; Lenalidomide; Placebo

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Pre Clinical Trial using brentuximab vedotin; doxorubicin hydrochloride; vinblastine; dacarbazine; quality-of-life assessment; DNA analysis; RNA analysis; fludeoxyglucose F 18; positron emission tomography; laboratory biomarker analysis; immunohistochemistry staining method; polymorphism analysis

Northwestern University - Recruiting 60 years or older.
- A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma.
brentuximab vedotin; doxorubicin hydrochloride; vinblastine; dacarbazine; quality-of-life assessment; DNA analysis; RNA analysis; fludeoxyglucose F 18; positron emission tomography; laboratory biomarker analysis; immunohistochemistry staining method; polymorphism analysis

B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or W Clinical Trial using AVL-292

Celgene Corporation - Recruiting 18 years or older.
- Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia.
AVL-292

Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Speci Clinical Trial using allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune (EBV)-Immune T-Lymphocytes Derived From Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases.
allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

T Cell Non-Hodgkin Lymphoma Clinical Trial using High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

Memorial Sloan-Kettering Cancer Center - Recruiting 16 years or older.
- A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma.
High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

Non Hematologic Cancers, Metastatic Cancer, or Lymphoma Clinical Trial using VS-5584

Verastem, Inc. - Recruiting 18 years or older.
- A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma.
VS-5584

Non-Hodgkin's Lymphoma Clinical Trial using ABT-199; Ketoconazole

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199.
ABT-199; Ketoconazole

Non-Hodgkin's Lymphoma Clinical Trial using ABT-199; Rifampin

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Effect of Rifampin on the Pharmacokinetics of ABT-199.
ABT-199; Rifampin

Tumor or Lymphoma Clinical Trial using JNJ-42756493

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.
JNJ-42756493

Lymphoma, Non-Hodgkin Clinical Trial using Ribomustin; rituximab

Astellas Pharma Inc - Recruiting 18 years or older.
- Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma.
Ribomustin; rituximab

Cerebral Lymphoma B Cell Refractory Clinical Trial using infusion of MYOCET

University Hospital, Brest - Recruiting 18 years or older.
- Phase II Study Evaluating the Combination Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy Containing High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine..
infusion of MYOCET

Lymphoma, B-Cell Clinical Trial using rituximab [MabThera/Rituxan]; CHOP

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Comparative, Randomized, Parallel-group, Multi-centre, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20 Positive Diffuse Large B-cell Lymphoma (DLBCL).
rituximab [MabThera/Rituxan]; CHOP

Non-Hodgkin's Lymphoma Clinical Trial using RO5072759; rituximab [MabThera/Rituxan]; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicentre, Phase III, Open Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) + Chemotherapy Compared to Rituximab + Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders..
RO5072759; rituximab [MabThera/Rituxan]; chemotherapy

Lymphoma Clinical Trial using MabThera/Rituxan; Standard chemotherapy

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Single Arm, Multicentre, Phase IIIb Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL).
MabThera/Rituxan; Standard chemotherapy

Non-Hodgkin's Lymphoma Clinical Trial using Mabthera intravenous; MabThera subcutaneous

Hoffmann-La Roche - Recruiting 18 years or older.
- A Two-stage Phase III, International, Multi-center, Randomized, Controlled, Open-label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV.
Mabthera intravenous; MabThera subcutaneous

Non-Hodgkin's Lymphoma Clinical Trial using rituximab [MabThera/Rituxan]; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- .
rituximab [MabThera/Rituxan]; chemotherapy

Lymphoma, B-Cell Clinical Trial using RO5072759; rituximab [MabThera/Rituxan]; CHOP chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase III, Multicenter, Open-label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL).
RO5072759; rituximab [MabThera/Rituxan]; CHOP chemotherapy

Lymphoma, B-Cell, Non-Hodgkin's Lymphoma Clinical Trial using rituximab [MabThera/Rituxan]; CHOP; CVP; bendamustine

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Randomized, Open-label, Multicenter Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a.
rituximab [MabThera/Rituxan]; CHOP; CVP; bendamustine

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Clinical Trial using Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Gilead Sciences - Recruiting 18 years or older.
- A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Clinical Trial using ofatumumab; cyclophosphamide; dexamethasone; doxorubicin hydrochloride; vincristine sulfate; cytarabine; autologous hematopoietic stem cell transplantation; methotrexate; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years to 69 years.
- Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell Lymphoma.
ofatumumab; cyclophosphamide; dexamethasone; doxorubicin hydrochloride; vincristine sulfate; cytarabine; autologous hematopoietic stem cell transplantation; methotrexate; laboratory biomarker analysis

Non-Hodgkin Lymphoma Clinical Trial using Bendamustine hydrochloride

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment.
Bendamustine hydrochloride

Lymphoma Clinical Trial using CD5789 0.01% Cream

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Exploratory Study to Evaluate the Safety and Efficacy of CD5789 in Subjects With Early Stage Cutaneous T-Cell Lymphoma.
CD5789 0.01% Cream

Carcinoma, Renal Cell, or Lymphoma, Mantle-Cell Clinical Trial using Temsirolimus (Non-Interventional Study)

Pfizer - Recruiting 18 years or older.
- INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus.
Temsirolimus (Non-Interventional Study)

Lymphoma Clinical Trial using socio-aesthetic care

University Hospital, Angers - Recruiting 18 years to 65 years.
- Impact of Socio-aesthetic Care in the Quality of Life of Patients Treated for Lymphoma During and After Hospitalization.
socio-aesthetic care

Graft Versus Host Disease, Leukemia, or Lymphoma Clinical Trial using rituximab; fludarabine phosphate; melphalan; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; indium In 111 ibritumomab tiuxetan; yttrium Y 90 ibritumomab tiuxetan; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years to 69 years.
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan.
rituximab; fludarabine phosphate; melphalan; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; indium In 111 ibritumomab tiuxetan; yttrium Y 90 ibritumomab tiuxetan; laboratory biomarker analysis

Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Mac Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies.
CB-839

Mantle Cell Lymphoma Clinical Trial using Bendamustine; Rituximab; Ibrutinib; Placebo

Janssen Research & Development, LLC - Recruiting 65 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma.
Bendamustine; Rituximab; Ibrutinib; Placebo

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using ACP-196

Acerta Pharma BV - Recruiting 18 years or older.
- A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia.
ACP-196

Leukemia, or Lymphoma Clinical Trial using HSCT; DLI

M.D. Anderson Cancer Center - Recruiting 1 year to 65 years.
- CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.
HSCT; DLI

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study.
PCI-32765 (Ibrutinib)

Lymphoma, or Nonneoplastic Condition Clinical Trial using bleomycin sulfate; filgrastim; ABVD regimen; BEACOPP regimen; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide; prednisone; procarbazine hydrochloride; vinblastine sulfate; vincristine sulfate

Southwest Oncology Group - Recruiting 18 years to 60 years.
- A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging.
bleomycin sulfate; filgrastim; ABVD regimen; BEACOPP regimen; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide; prednisone; procarbazine hydrochloride; vinblastine sulfate; vincristine sulfate

Adult Acute Lymphoblastic Leukemia in Remission, Adult Nasal Type Clinical Trial using dasatinib; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
dasatinib; pharmacological study

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies.
indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation

Recurrent Adult Hodgkin Lymphoma Clinical Trial using temsirolimus; brentuximab vedotin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma.
temsirolimus; brentuximab vedotin; laboratory biomarker analysis

Leukemia, or Lymphoma Clinical Trial using Needs Analysis; Video game; Interview

M.D. Anderson Cancer Center - Recruiting 15 years to 29 years.
- Using Game Mechanics to Improve Outcomes Among Stem Cell Transplant Survivors.
Needs Analysis; Video game; Interview

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 68 years.
- Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia.
Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

Hematologic Neoplasms, Neural Tube Defects, or Myeloproliferative Clinical Trial using therapeutic allogeneic lymphocytes; Sirolimus

National Institutes of Health Clinical Center (CC) - Recruiting 11 years to 90 years.
- Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome.
therapeutic allogeneic lymphocytes; Sirolimus

Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disea Clinical Trial using Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years.
- Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders.
Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

Renal Cell Carcinoma, Breast Cancer, Colon Cancer, Lung Cancer, o Clinical Trial using dimethane sulfonate (DMS612, NSC 281612)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies.
dimethane sulfonate (DMS612, NSC 281612)

Monoclonal B-Cell Lymphocytosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers..

Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), No Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment.

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, or Desmoplastic Small Clinical Trial using Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 35 years.
- A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias.
Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

Neoplasms, or Lymphoma Clinical Trial using MK-1775

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Single-agent MK-1775, a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors.
MK-1775

Lymphoma, or Leukemia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy.

Autoimmune Lymphoproliferative Syndrome, or Lymphoma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 5 years or older.
- Use of Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography for the Evaluation of Autoimmune Lymphoproliferative Syndrome Lymphadenopathy Suggestive of Lymphoma..

Small Lymphocytic Lymphoma, or CLL (Chronic Lymphocytic Leukemia) Clinical Trial using Fludarabine Phosphate; Ofatumumab; Cyclophosphamide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Fludarabine Phosphate; Ofatumumab; Cyclophosphamide

Lymphoma, Large B-Cell, Diffuse Clinical Trial using CC-122; CC-223; Rituximab; CC-292

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292 and Rituximab in Diffuse Large B-cell Lymphoma.
CC-122; CC-223; Rituximab; CC-292

Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed F Clinical Trial using Pixantrone + Rituximab; Gemcitabine + Rituximab

Cell Therapeutics - Recruiting 18 years or older.
- A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant.
Pixantrone + Rituximab; Gemcitabine + Rituximab

Ewing's Sarcoma, Leukemia, Lymphoma, Neoplasm, or Sarcoma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 3 Months to 40 years.
- Treatment of Children With Cancer.

Non Hodgkin's Lymphoma Clinical Trial using filgrastim; Rituximab

National Institutes of Health Clinical Center (CC) - Recruiting 12 years or older.
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma.
filgrastim; Rituximab

Hematologic Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Clinical Trial using Stem cell transplantation

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases.
Stem cell transplantation

Lymphoma Clinical Trial using Biopsy; Fluordeoxyglucose F 18; [3'-deoxy-3'-[F-18] fluorothymidine; computed tomography; fine-needle aspiration

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study of 18F Fluorothymidine (FLT) PET/CT in Lymphoma.
Biopsy; Fluordeoxyglucose F 18; [3'-deoxy-3'-[F-18] fluorothymidine; computed tomography; fine-needle aspiration

Cutaneous Lymphoma, Other Skin Disorders, Mycosis Fungoides, or C Clinical Trial

Stanford University - Recruiting 18 years or older.
- Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing.

Neoplasms, or Lymphoma Clinical Trial using LMP 400; LMP 776

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas.
LMP 400; LMP 776

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphom Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol.

Hodgkin Disease, or Hodgkin Lymphoma Clinical Trial using Filgrastim; Plerixafor; Yttrium-Daclizumab (CHX-A Daclizumab); Carmustine; Etoposide; Cytarabine; Melphalan; Ca(2+)-DTPA

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin s Lymphoma.
Filgrastim; Plerixafor; Yttrium-Daclizumab (CHX-A Daclizumab); Carmustine; Etoposide; Cytarabine; Melphalan; Ca(2+)-DTPA

Non-Hodgkin Lymphoma, Multiple Myleoma, Chronic Lympocytic Leukem Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 79 years.
- A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph).

Aplastic Anemia, Leukemia, Myelodysplastic Syndrome (MDS), or Lym Clinical Trial using Cord Blood Units

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients.
Cord Blood Units

CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma Clinical Trial using AEB071; Everolimus

Novartis - Recruiting 18 years or older.
- An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma.
AEB071; Everolimus

Leukemia, or Lymphoma Clinical Trial using DT2219ARL

Masonic Cancer Center, University of Minnesota - Recruiting 12 years or older.
- A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma.
DT2219ARL

Anaplastic Lymphoma Kinase (ALK), or Non-small Cell Lung Cancer Clinical Trial using LDK378; AUY922

Novartis - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer.
LDK378; AUY922

Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, or High Grade B- Clinical Trial using Rituximab; IT Cytarabine

New York Medical College - Recruiting 3 years to 31 years.
- Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma.
Rituximab; IT Cytarabine

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies.
yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Indolent B-cell Lymphoma, or Chronic Lymphocytic Leukaemia Clinical Trial using DI-B4

Cancer Research UK - Recruiting 18 years or older.
- A Cancer Research UK Phase I Trial of the Anti-CD19 DI-B4 Monoclonal Antibody Given Intravenously, Weekly for Four Weeks, in Patients With Advanced CD19 Positive Indolent B-cell Malignancies.
DI-B4

Non-Hodgkin's Lymphoma, or Active Solid Malignancy Clinical Trial using PET Imaging using 124 IPUH71

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 90 years.
- PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study.
PET Imaging using 124 IPUH71

Lymphoma Clinical Trial using Romidepsin; Ifosfamide; Mesna; Carboplatin; Etoposide

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I Study of Romidepsin (ISTODAXr) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
Romidepsin; Ifosfamide; Mesna; Carboplatin; Etoposide

Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic T Clinical Trial using alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

St. Jude Children's Research Hospital - Recruiting 2 years to 21 years.
- A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas.
alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphob Clinical Trial using Clofarabine; Mitoxantrone

New York Medical College - Recruiting N/A to 30 years.
- A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma.
Clofarabine; Mitoxantrone

Lymphoma, Non Hodgkin Clinical Trial using rituximab [MabThera/Rituxan]

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- OPEN LABEL, SINGLE-ARM, PHASE IIIb CLINICAL TRIAL TO EVALUATE THE SAFETY OF SWITCHING FROM INTRAVENOUS RITUXIMAB TO SUBCUTANEOUS RITUXIMAB DURING FIRST LINE TREATMENT FOR CD20+ NON-HODGKIN'S FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA..
rituximab [MabThera/Rituxan]

Lymphoblastic Leukemia, Acute T-cell, or Precursor T-Cell Lymphob Clinical Trial using BMS-906024; Dexamethasone

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.
BMS-906024; Dexamethasone

Lymphoma Clinical Trial using rituximab; bendamustine hydrochloride; cyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride; leucovorin calcium; methotrexate; vincristine sulfate

Southwest Oncology Group - Recruiting 18 years to 65 years.
- A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients ó 65 Years of Age With Previously Untreated Mantle Cell Lymphoma.
rituximab; bendamustine hydrochloride; cyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride; leucovorin calcium; methotrexate; vincristine sulfate

Lymphoma, or B-cell Lymphoma Clinical Trial using Leukapheresis; Stem Cell Transplant; CD19-specific T Cell Infusion; IL-2; Carmustine; Etoposide; Cytarabine; Melphalan; Rituximab

M.D. Anderson Cancer Center - Recruiting 18 years to 65 years.
- CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Autologous Hematopoietic Stem Cell Transplantation.
Leukapheresis; Stem Cell Transplant; CD19-specific T Cell Infusion; IL-2; Carmustine; Etoposide; Cytarabine; Melphalan; Rituximab

Solid Tumors, Lymphoma, or Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib; Gefitinib

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies.
LY2875358; Erlotinib; Gefitinib

Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or Hodgkin Disease Clinical Trial using Antigen Escalation Stage; Dose escalation study of T cells

Baylor College of Medicine - Recruiting N/A or older.
- Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma.
Antigen Escalation Stage; Dose escalation study of T cells

Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Di Clinical Trial using LMP, BARF1 & EBNA1 specific CTLs: A; LMP, BARF1 & EBNA1 specific CTLs : B

Baylor College of Medicine - Recruiting N/A or older.
- Administration of Rapidly Generated LMP, BARF1 And EBNA1 Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma.
LMP, BARF1 & EBNA1 specific CTLs: A; LMP, BARF1 & EBNA1 specific CTLs : B

Neoplasms, or Lymphoma Clinical Trial using Part 1: JNJ-42756493; Part 2: JNJ-42756493

Janssen Research & Development, LLC - Recruiting 20 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.
Part 1: JNJ-42756493; Part 2: JNJ-42756493

Hematopoietic/Lymphoid Cancer Clinical Trial using brentuximab vedotin; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 12 years to 75 years.
- Maintenance Therapy With Brentuximab Vedotin (SGN-35) After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies.
brentuximab vedotin; laboratory biomarker analysis; pharmacological study

Advanced Solid Tumors, or Lymphoma Clinical Trial using MLN9708

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1 Study of [14C]-MLN9708 to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas.
MLN9708

Lymphoma, Follicular Clinical Trial using Ofatumumab; Rituximab

GlaxoSmithKline - Recruiting 18 years or older.
- Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy.
Ofatumumab; Rituximab

Recurrent or Refractory PTCL Clinical Trial using forodesine hydrochloride

Mundipharma K.K. - Recruiting 20 years or older.
- Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients.
forodesine hydrochloride

Advanced Solid Tumors, or Lymphomas Clinical Trial using Camptothecin-20-O-Propionate Hydrate (CZ48)

New Mexico Cancer Care Alliance - Recruiting 18 years or older.
- Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma.
Camptothecin-20-O-Propionate Hydrate (CZ48)

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using High Dose Methylprednisolone (HDMP); Ofatumumab; Lenalidomide

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial.
High Dose Methylprednisolone (HDMP); Ofatumumab; Lenalidomide

Diffuse Large B-Cell Lymphoma Clinical Trial using Bendamustine; Ofatumumab

SCRI Development Innovations, LLC - Recruiting 70 years or older.
- Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.
Bendamustine; Ofatumumab

Lymphoma Clinical Trial using Carfilzomib; Lenalidomide; Rituximab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I/II Study of Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.
Carfilzomib; Lenalidomide; Rituximab

Follicular Non-Hodgkin's Lymphoma Clinical Trial using R-CHOP; Observation; Maintenance weekly x4; Ibritumomab Tiuxetan + Maintenance; Standard Maintenance

Fondazione Italiana Linfomi ONLUS - Recruiting 18 years or older.
- A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma..
R-CHOP; Observation; Maintenance weekly x4; Ibritumomab Tiuxetan + Maintenance; Standard Maintenance

Solid Tumors, Lymphoma, or Multiple Myeloma Clinical Trial using CS-7017 and Bexarotene

Georgetown University - Recruiting 18 years or older.
- A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene.
CS-7017 and Bexarotene

Diffuse Large B-Cell Lymphoma Clinical Trial using Rituximab, CMC544, Gemcitabine and Oxaliplatine

The Lymphoma Academic Research Organisation - Recruiting 18 years to 80 years.
- A Multi-center, Phase IB/II, Open Label, Single Arm Study of Inotuzumab Ozogamicin Plus Rituximab (R-CMC544) Alternating With Gemcitabine-oxaliplatin Plus Rituximab(R-GEMOX)in Patients Aged From 18 to 80 Years With CD20 and CD22 Positive Diffuse Large B-cell Lymphoma (DLBCL) in Relapse After/Refractory to 1ST or 2ND Line Treatment, Who Are no Candidates for Autologous Transplant..
Rituximab, CMC544, Gemcitabine and Oxaliplatine

Follicular Lymphoma Patients (Phase IB), or Follicular and Agress Clinical Trial using Lenalidomide and GA101

The Lymphoma Academic Research Organisation - Recruiting 18 years or older.
- A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma.
Lenalidomide and GA101

Cutaneous T-Cell Lymphoma Clinical Trial using KW-0761; Vorinostat

Kyowa Hakko Kirin Pharma, Inc. - Recruiting 18 years or older.
- Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma.
KW-0761; Vorinostat

Relapsed/Refractory B-cell Lymphoma Clinical Trial using CC-292 + lenalidomide

The Lymphoma Academic Research Organisation - Recruiting 18 years or older.
- A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA.
CC-292 + lenalidomide

Leukemia, Lymphoma, or Hematologic Diseases Clinical Trial using collection and storage of tissue samples for research

Stanford University - Recruiting N/A to 70 years.
- Bone Marrow Grafting for Leukemia and Lymphoma.
collection and storage of tissue samples for research

Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Clinical Trial using clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant.
clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marro Clinical Trial using anti-thymocyte globulin; cyclosporine

Stanford University - Recruiting 18 years or older.
- A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma.
anti-thymocyte globulin; cyclosporine

Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Adva Clinical Trial using FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Amgen - Recruiting 18 years or older.
- A Phase 2 Open Label Extension Study of Conatumumab and AMG 479.
FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Advanced Cancers, DLBCL, or Lymphoma Clinical Trial using ISIS-STAT3Rx

Isis Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers.
ISIS-STAT3Rx

Lymphoma, Non-Hodgkin, or Hodgkin's Disease Clinical Trial

Stanford University - Recruiting 18 years or older.
- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease.

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL, or Clinical Trial using A6

ngstrom Pharmaceuticals - Recruiting 18 years or older.
- A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia.
A6

Non-Hodgkin's Lymphoma (NHL) Clinical Trial using temsirolimus

Pfizer - Recruiting 18 years or older.
- A Randomized Phase 4 Study Comparing 2 Doses Of Intravenous Temsirolimus In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL).
temsirolimus

Lymphoma, B-Cell Clinical Trial using inotuzumab ozogamicin

Pfizer - Recruiting 18 years or older.
- A Phase 1/2 Study Of CMC-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-Cell Non-Hodgkin's Lymphoma.
inotuzumab ozogamicin

Advanced Solid Tumors, or Lymphoma Clinical Trial using MLN8237

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas.
MLN8237

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Solid Tumors, or Lymphoma Clinical Trial using alisertib; esomeprazole; rifampin

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas.
alisertib; esomeprazole; rifampin

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Lymphoma Clinical Trial using cyclophosphamide; cyclosporine; fludarabine phosphate; gemcitabine hydrochloride; ifosfamide; mechlorethamine hydrochloride; melphalan; methotrexate; mycophenolate mofetil; prednisone; procarbazine hydrochloride; vincristine sulfate; vinorelbine tartrate; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; umbilical cord blood transplantation; total-body irradiation

Memorial Sloan-Kettering Cancer Center - Recruiting 13 years to 65 years.
- An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma.
cyclophosphamide; cyclosporine; fludarabine phosphate; gemcitabine hydrochloride; ifosfamide; mechlorethamine hydrochloride; melphalan; methotrexate; mycophenolate mofetil; prednisone; procarbazine hydrochloride; vincristine sulfate; vinorelbine tartrate; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; umbilical cord blood transplantation; total-body irradiation

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosi Clinical Trial using carfilzomib; romidepsin; laboratory biomarker analysis

Northwestern University - Recruiting 18 years or older.
- A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma.
carfilzomib; romidepsin; laboratory biomarker analysis

Diffuse Large B-Cell Lymphoma Clinical Trial using Gemcitabine; Methylprednisolone; Rituximab; Cisplatin; Lenalidomide

Royal Marsden NHS Foundation Trust - Recruiting 18 years or older.
- A Randomised Phase II Study Comparing LEnalidomide Plus Rituximab, GEmcitabine and Methylprednisolone (LR-GEM) to Rituximab, Gemcitabine, Methylprednisolone and cisplatiN (R-GEM-P) in Second-line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)..
Gemcitabine; Methylprednisolone; Rituximab; Cisplatin; Lenalidomide

Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, or Gastro Clinical Trial using Temsirolimus; Sunitinib; Axitinib

Pfizer - Recruiting 18 years or older.
- STAR-TOR - Registry for the Evaluation of the Safety, Tolerability and Efficacy of Temsirolimus (Toriselr), Sunitinib (Sutentr), and Axitnib (Inlytar) for the Treatment of Subjects With Advanced Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), and Gastro-Intestinal Stroma Tumor (GIST).
Temsirolimus; Sunitinib; Axitinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using PF-02341066

Pfizer - Recruiting 18 years or older.
- Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Non-Small Cell Lung Cancer Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene.
PF-02341066

NSCLC (Non-small Cell Lung Cancer) Clinical Trial using Crizotinib; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin

Pfizer - Recruiting 18 years to 70 years.
- Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated East Asian Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Crizotinib; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin

Lymphoma, Non-Hodgkin Clinical Trial using PF-05082566; rituximab

Pfizer - Recruiting 18 years or older.
- A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL).
PF-05082566; rituximab

Systemic Anaplastic Large-Cell Lymphoma, Neoplasms, Anaplastic Ly Clinical Trial using PF-02341066; Rifampin; Ketoconazole

Pfizer - Recruiting 18 years or older.
- Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of PF-02341066, A c-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer.
PF-02341066; Rifampin; Ketoconazole

Recurrent Adult Diffuse Large Cell Lymphoma Clinical Trial using selumetinib; diagnostic laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Single-Arm Phase II Clinical Trial With the Novel MEK Inhibitor AZD-6244 for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
selumetinib; diagnostic laboratory biomarker analysis

Advanced Solid Tumor, or Lymphomas Clinical Trial using LEE011

Novartis - Recruiting 18 years or older.
- A phase1 Multi-center, Open Label, Dose-escalation Study of Oral LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
LEE011

Lymphoma Clinical Trial using AUY922

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma.
AUY922

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL.
ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using ipilimumab; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma.
ipilimumab; rituximab; laboratory biomarker analysis

Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplanta Clinical Trial using Melphalan; Fludarabine; Mycophenolate mofetil; Tacrolimus; Cord Blood Infusion; Rituximab; ATG; Busulfan; Clofarabine; Total Body Irradiation (TBI)

M.D. Anderson Cancer Center - Recruiting 1 year to 80 years.
- Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies.
Melphalan; Fludarabine; Mycophenolate mofetil; Tacrolimus; Cord Blood Infusion; Rituximab; ATG; Busulfan; Clofarabine; Total Body Irradiation (TBI)

Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Clinical Trial using plerixafor; filgrastim; etoposide; leukapheresis

Case Comprehensive Cancer Center - Recruiting 18 years to 78 years.
- A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma.
plerixafor; filgrastim; etoposide; leukapheresis

Lymphoma, or Hodgkin Disease Clinical Trial using tumor tissue aspiration; phlebotomy

Stanford University - Recruiting N/A to 21 years.
- Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy.
tumor tissue aspiration; phlebotomy

Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Clinical Trial using brentuximab vedotin; etoposide; prednisone; doxorubicin; cyclophosphamide; Dacarbazine(R); filgrastim; quality of life assessment; radiation therapy

St. Jude Children's Research Hospital - Recruiting N/A to 18 years.
- Adcetris Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Low Dose Tailored-Field Radiation Therapy for Unfavorable Risk Pediatric Hodgkin Lymphoma.
brentuximab vedotin; etoposide; prednisone; doxorubicin; cyclophosphamide; Dacarbazine(R); filgrastim; quality of life assessment; radiation therapy

Mature B-Cell Lymphoma Clinical Trial using COPAD; COP, COPD M3, CYM; COP, COPADM8, CYVE

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- Mature B-Cell Lymphoma And Leukemia Study III.
COPAD; COP, COPD M3, CYM; COP, COPADM8, CYVE

B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Diffuse Clinical Trial using rituximab; prednisone; etoposide; doxorubicin hydrochloride; cytarabine; vincristine sulfate; cyclophosphamide; methotrexate; methylprednisolone; leucovorin calcium; therapeutic hydrocortisone

Children's Oncology Group - Recruiting N/A to 18 years.
- Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients.
rituximab; prednisone; etoposide; doxorubicin hydrochloride; cytarabine; vincristine sulfate; cyclophosphamide; methotrexate; methylprednisolone; leucovorin calcium; therapeutic hydrocortisone

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using survey administration; assessment of therapy complications; long-term screening; study of high risk factors

Children's Oncology Group - Recruiting N/A or older.
- Umbrella Long-Term Follow-Up Protocol.
survey administration; assessment of therapy complications; long-term screening; study of high risk factors

Diffuse, Large B-Cell, Lymphoma Clinical Trial using Bortezomib; Rituximab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine

Grupo Espa¤ol de Linfomas y Transplante Aut¢logo de M‚dula Osea - Recruiting 18 years to 70 years.
- Multicenter Randomized Phase II Study of Treatment With R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI..
Bortezomib; Rituximab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine

Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individual With Cancer.

Non-Hodgkins Lymphoma, Hodgkins Lymphoma, or Lymphoproliferative Clinical Trial using EBV CTL's; Peripheral Blood Donor

New York Medical College - Recruiting 1 year or older.
- A Multicenter Pilot Study of Third Party LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Refractory /Relapsed EBV-Associated Lymphoma A Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) Multicenter Clinical Trial.
EBV CTL's; Peripheral Blood Donor

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies.
Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Non-Hodgkin's Lymphoma Clinical Trial using Bendamustine; Ofatumumab; Carboplatin; Etoposide; CT Scan; PET Scan; Stem Cell Transplant (STC)

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas.
Bendamustine; Ofatumumab; Carboplatin; Etoposide; CT Scan; PET Scan; Stem Cell Transplant (STC)

Indolent Non-Hodgkin's Lymphoma Clinical Trial using Arm A: Rituximab; Arm B: GA101

PrECOG, LLC. - Recruiting 18 years or older.
- Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma.
Arm A: Rituximab; Arm B: GA101

B-cell Non-Hodgkin Lymphoma Clinical Trial using 0.5 mg/m2 DI-Leu16-IL2; 1.0 mg/m2 DI-Leu16-IL2; 2.0 mg/m2 DI-Leu16-IL2; 4.0 mg/m2 DI-Leu16-IL2; 6.0 mg/m2 DI-Leu16-IL2; 8.0 mg/m2 DI-Leu16-IL2; 10.0 mg/m2 DI-Leu16-IL2

Alopexx Oncology, LLC - Recruiting 18 years or older.
- A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL).
0.5 mg/m2 DI-Leu16-IL2; 1.0 mg/m2 DI-Leu16-IL2; 2.0 mg/m2 DI-Leu16-IL2; 4.0 mg/m2 DI-Leu16-IL2; 6.0 mg/m2 DI-Leu16-IL2; 8.0 mg/m2 DI-Leu16-IL2; 10.0 mg/m2 DI-Leu16-IL2

Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma, Clinical Trial using rituximab

Biocad - Recruiting 18 years to 95 years.
- A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma.
rituximab

Relapsed Lymphoblastic Leukemia, Relapsed Lymphoblastic Lymphoma, Clinical Trial using Sirolimus

Children's Hospital Medical Center, Cincinnati - Recruiting N/A to 30 years.
- Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma.
Sirolimus

T-Cell Lymphoma, Relapsed T-Cell Lymphoma, or Refractory T-Cell L Clinical Trial using PEG-L-asparaginase; Dexamethasone acetate

Dana-Farber Cancer Institute - Recruiting 18 years to 65 years.
- A Pilot Study of Oncasparr + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma.
PEG-L-asparaginase; Dexamethasone acetate

Lymphoma Clinical Trial using Cardiac Magnetic Resonance Scan

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Non-invasive Detection of Cardiac Fibrosis After Administration of Doxorubicin-Based Chemotherapy in Patients With Lymphoma Using Cardiac Magnetic Resonance: A Pilot Study.
Cardiac Magnetic Resonance Scan

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using alisertib; romidepsin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas.
alisertib; romidepsin; laboratory biomarker analysis

Leukemia, or Lymphoma Clinical Trial using Rituximab; Lenalidomide

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy.
Rituximab; Lenalidomide

T-cell Non-Hodgkin Lymphoma Clinical Trial using Cyclophosphamide; Doxorubicin; Vincristine; Etoposide; Prednisone; Filgrastim; Plerixafor; Stem Cell Collection; Palifermin; Gemcitabine; Busulfan; Melphalan; Stem Cell Transplant

Dana-Farber Cancer Institute - Recruiting 18 years to 70 years.
- A Phase II Study of CHOEP Induction Followed by Gemcitabine/Busulfan/Melphalan Autologous Stem Cell Transplantation for Patients With Newly Diagnosed T-Cell Lymphoma.
Cyclophosphamide; Doxorubicin; Vincristine; Etoposide; Prednisone; Filgrastim; Plerixafor; Stem Cell Collection; Palifermin; Gemcitabine; Busulfan; Melphalan; Stem Cell Transplant

Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicul Clinical Trial using ibrutinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma.
ibrutinib; laboratory biomarker analysis

Anaplastic Large-cell Lymphoma Clinical Trial using brentuximab vedotin

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
brentuximab vedotin

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Chronic Lymphocytic Leukemia, or Mantle Cell Lymphoma Clinical Trial using Ublituximab; Ibrutinib

TG Therapeutics, Inc. - Recruiting 18 years or older.
- A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies.
Ublituximab; Ibrutinib

Advanced Solid Tumor, or Lymphoma Clinical Trial using DS-3032

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas.
DS-3032

Peripheral T-cell Lymphoma Clinical Trial

Spectrum Pharmaceuticals, Inc - Recruiting N/A or older.
- Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma.

Lymphoma, Non-Hodgkin's Clinical Trial using PNT2258

Pronai Therapeutics, Inc - Recruiting 18 years or older.
- PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma.
PNT2258

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma Clinical Trial using Urelumab (BMS-663513)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL).
Urelumab (BMS-663513)

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using Ibrutinib; Bendamustine hydrochloride; Rituximab; Placebo

Janssen Research & Development, LLC - Recruiting 18 years or older.
- Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ibrutinib; Bendamustine hydrochloride; Rituximab; Placebo

Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, or Chronic L Clinical Trial using SAR245409

Sanofi - Recruiting 18 years or older.
- A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
SAR245409

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, or Lymp Clinical Trial using BPX-501 and AP1903

Bellicum Pharmaceuticals - Recruiting 18 years to 65 years.
- A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant).
BPX-501 and AP1903

Leukemia, Myelodysplastic Syndrome, or Lymphoma Clinical Trial using CliniMACS Fractionation system (Arm A); CliniMACS Fractionation system (Arm B)

Memorial Sloan-Kettering Cancer Center - Recruiting 2 years to 70 years.
- Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies.
CliniMACS Fractionation system (Arm A); CliniMACS Fractionation system (Arm B)

Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chroni Clinical Trial using BMS-936564 (Anti-CXCR4)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies.
BMS-936564 (Anti-CXCR4)

Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, or Non-Hodg Clinical Trial using Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 60 years.
- An Open Label Randomized Phase II Study of Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation.
Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Peripheral T-Cell Lymphoma Clinical Trial using denileukin diftitox (E7777)

Eisai Inc. - Recruiting 20 years to 79 years.
- Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma.
denileukin diftitox (E7777)

Leukemia Clinical Trial using therapeutic autologous lymphocytes; cyclophosphamide

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19.
therapeutic autologous lymphocytes; cyclophosphamide

Diffuse Large B-cell Lymphoma Clinical Trial using Blinatumomab

Amgen Research (Munich) GmbH - Recruiting 18 years or older.
- An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE) Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).
Blinatumomab

Indolent Non-Hodgkin Lymphoma Clinical Trial using IPI-145

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO).
IPI-145

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Solid Tumors and Non-Hodgkin's Lymphoma Clinical Trial using LY2780301; Gemcitabine

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose Escalation Study of the Safety, Tolerability and Efficacy of LY2780301 (a p70/AKT Inhibitor) in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer.
LY2780301; Gemcitabine

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using PCI-32765

Pharmacyclics - Recruiting 65 years or older.
- An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil).
PCI-32765

Acute Lymphocytic Leukemia, or Adult Lymphoblastic Lymphoma Clinical Trial using DNR; VCR; PEG-asp; CTX; Prednisone; Liposomal AraC; MTX; LCV; AraC; Etoposide; Dasatinib; Rituximab; Hydrocortisone

University of California, San Diego - Recruiting 18 years to 60 years.
- A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocytr) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
DNR; VCR; PEG-asp; CTX; Prednisone; Liposomal AraC; MTX; LCV; AraC; Etoposide; Dasatinib; Rituximab; Hydrocortisone

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non Clinical Trial using autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years or older.
- Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma.
autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Breast Cancer, Prostate Cancer, Lung Cancer, Lymphoma Cancer, or Clinical Trial using group intervention and questionnaires; individual phone intervention and questionnaires

Memorial Sloan-Kettering Cancer Center - Recruiting 70 years or older.
- Pilot of a Geriatric Group Psychoeducational Intervention for Elderly Patients With Cancer.
group intervention and questionnaires; individual phone intervention and questionnaires

Chronic Lymphocytic Leukemia Clinical Trial using SyB L-0501

SymBio Pharmaceuticals - Recruiting 20 years to 80 years.
- A Multicenter, Open-label Phase II Study of SyB L-0501 in Patients With Chronic Lymphocytic Lymphoma.
SyB L-0501

Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Diffuse Clinical Trial using doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma.
doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

Recurrent Adult Hodgkin Lymphoma, or Recurrent/Refractory Childho Clinical Trial using brentuximab vedotin; gemcitabine hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 13 Months to 30 years.
- A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND# 117117) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma.
brentuximab vedotin; gemcitabine hydrochloride; laboratory biomarker analysis

Stage II Childhood Anaplastic Large Cell Lymphoma, Stage III Chil Clinical Trial using brentuximab vedotin; crizotinib; dexamethasone; ifosfamide; methotrexate; cytarabine; etoposide; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) IND # 117117.
brentuximab vedotin; crizotinib; dexamethasone; ifosfamide; methotrexate; cytarabine; etoposide; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis

Peripheral T-cell Lymphoma Clinical Trial using Pralatrexate Injection

Spectrum Pharmaceuticals, Inc - Recruiting 18 years or older.
- A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy.
Pralatrexate Injection

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.
alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

Sarcoma, Wilm's Tumor, Lymphoma, or Neuroblastoma Clinical Trial using Ipilimumab(anti-CTLA-4 antibody)

National Institutes of Health Clinical Center (CC) - Recruiting 1 year to 21 years.
- A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer.
Ipilimumab(anti-CTLA-4 antibody)

Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy.
Nivolumab

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, o Clinical Trial using auranofin

University of Kansas - Recruiting 18 years or older.
- A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL).
auranofin

Solid Tumors, or Lymphoma Clinical Trial using PU-H71

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma.
PU-H71

Diffuse Large B Cell Lymphoma Clinical Trial using LBH589; Rituximab

Jewish General Hospital - Recruiting 18 years or older.
- A Randomized Phase II Study of Oral Panobinostat (LBH589) With or Without Rituximab to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma.
LBH589; Rituximab

Neoplasms, Neoplasm Metastasis, or Lymphoma Clinical Trial using LY3039478

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer.
LY3039478

Non-Hodgkin's Lymphoma (NHL) Clinical Trial using [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Bayer - Recruiting N/A or older.
- Drug Use Investigation of Zevalin.
[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

NHL Subjects Who Have Failed Prior Systemic Therapy Clinical Trial using ADI-PEG 20

Polaris Group - Recruiting 20 years or older.
- Phase 2 Study of ADI PEG 20 in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy.
ADI-PEG 20

Neoplasm Malignant Clinical Trial using SAR245409

Sanofi - Recruiting 18 years or older.
- A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma.
SAR245409

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; bortezomib; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma.
alisertib; bortezomib; rituximab; laboratory biomarker analysis

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using romidepsin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
romidepsin; pharmacological study

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Clinical Trial using Rituximab and Lenalidomide

Arbeitsgemeinschaft medikamentoese Tumortherapie - Recruiting 18 years or older.
- Phase II Trial of Rituximab Plus Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type.
Rituximab and Lenalidomide

Diffuse Large Cell Lymphoma Relapsed/Refractory Clinical Trial using Ofatumumab; Etoposide; Cytarabine

University of California, San Francisco - Recruiting 18 years or older.
- A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy With Ofatumumab, Etoposide, and High-dose Ara-C (OVA), Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Ofatumumab; Etoposide; Cytarabine

Hypertriglyceridemia, or Cutaneous T Cell Lymphoma Clinical Trial using oral glucose tolerance test (OGTT)

Rennes University Hospital - Recruiting 18 years or older.
- Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study.
oral glucose tolerance test (OGTT)

Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemi Clinical Trial using PCI 32765

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion.
PCI 32765

Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, or Lymphom Clinical Trial using LTX-315

Lytix Biopharma AS - Recruiting 18 years or older.
- A Phase I, Open-label, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 in Patients With Transdermally Accessible Tumours.
LTX-315

B-Cell Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocyto Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute L Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Relapsed Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation: Screening, Disease Characterization and Natural History.

MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymp Clinical Trial using Graft Manipulation (CD34+ Selection)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies.
Graft Manipulation (CD34+ Selection)

Lymphoma, Non-Hodgkin, or Hodgkin Disease Clinical Trial using Abraxane

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma.
Abraxane

Lymphoblastic Leukemia, or Lymphoblastic Lymphoma Clinical Trial using Daunorubicin; Vincristine; PEG-asparaginase; Intrathecal Methotrexate; Cyclophosphamide; Cytarabine; Mercaptopurine; Methotrexate; Doxorubicin; Thioguanine

M.D. Anderson Cancer Center - Recruiting 12 years to 40 years.
- Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma.
Daunorubicin; Vincristine; PEG-asparaginase; Intrathecal Methotrexate; Cyclophosphamide; Cytarabine; Mercaptopurine; Methotrexate; Doxorubicin; Thioguanine

Leukemia, Lymphoma, Allogeneic Haematopoietic Stem Cell Transplan Clinical Trial using Busulfan; Clofarabine; Thymoglobulin; Stem Cell Transplant

M.D. Anderson Cancer Center - Recruiting N/A to 65 years.
- Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia.
Busulfan; Clofarabine; Thymoglobulin; Stem Cell Transplant

Advanced Solid Tumor and Lymphoma Malignancies Clinical Trial using TAK-659

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies.
TAK-659

Leukemia, or Lymphoma Clinical Trial using valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL.
valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

Lymphoma Clinical Trial using Ibrutinib; Placebo; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone (or equivalent)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma.
Ibrutinib; Placebo; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone (or equivalent)

Lymphoma Clinical Trial using autologous immunoglobulin idiotype-KLH conjugate vaccine; rituximab; sargramostim

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Maintenance Rituximab Plus FavIdr and GM-CSF Immunotherapy in Patients With Treatment-Naive Indolent B-Cell Lymphoma.
autologous immunoglobulin idiotype-KLH conjugate vaccine; rituximab; sargramostim

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Clinical Trial using filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 16 years to 65 years.
- A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies.
filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Sta Clinical Trial using MOR00208; lenalidomide; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years to 80 years.
- A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients With Untreated CLL/SLL/PLL.
MOR00208; lenalidomide; Correlative Studies

Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia Clinical Trial using anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells.
anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma Clinical Trial using Idelalisib; Rituximab

Gilead Sciences - Recruiting 65 years or older.
- A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Idelalisib; Rituximab

Follicular Lymphoma, B-cell Lymphoma, or Non-Hodgkin's Lymphoma Clinical Trial using Ibrutinib; rituximab

Pharmacyclics - Recruiting 18 years or older.
- A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma.
Ibrutinib; rituximab

Neoplasm Metastasis, or Lymphoma Clinical Trial using LY2835219

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2835219 in Japanese Patients With Advanced Cancer.
LY2835219

CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lympho Clinical Trial using SGN-35

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP).
SGN-35

Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas Clinical Trial using CART-19

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas.
CART-19

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic M Clinical Trial using iTreg

Masonic Cancer Center, University of Minnesota - Recruiting 18 years to 75 years.
- Dose Escalation Study With Extension of Inducible Regulatory T Cells (iTregs) in Adult Patients Undergoing Non-Myeloablative HLA Identical Sibling Donor Peripheral Blood Stem Cell Transplantation.
iTreg

Non-Hodgkin's Lymphoma Clinical Trial using ABT-199; Bendamustine; Rituximab

AbbVie - Recruiting 18 years or older.
- A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma.
ABT-199; Bendamustine; Rituximab

Hodgkin Lymphoma Clinical Trial using brentuximab vedotin; doxorubicin; bleomycin; vinblastine; dacarbazine

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma.
brentuximab vedotin; doxorubicin; bleomycin; vinblastine; dacarbazine

Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage Clinical Trial using ofatumumab; bendamustine hydrochloride; bortezomib; laboratory biomarker analysis; positron emission tomography with radiolabeled targeting agents; fludeoxyglucose F 18

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma.
ofatumumab; bendamustine hydrochloride; bortezomib; laboratory biomarker analysis; positron emission tomography with radiolabeled targeting agents; fludeoxyglucose F 18

Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontigu Clinical Trial using lenalidomide; rituximab; cyclophosphamide; doxorubicin hydrochloride; vincristine sulfate; prednisone; laboratory biomarker analysis; positron emission tomography

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
lenalidomide; rituximab; cyclophosphamide; doxorubicin hydrochloride; vincristine sulfate; prednisone; laboratory biomarker analysis; positron emission tomography

Stem Cell Transplantation, Leukemia, or Lymphoma Clinical Trial using Thiotepa; Clofarabine; Busulfan; Allogeneic Stem Cell Transplantation; Thymoglobulin (ATG); G-CSF (Filgrastim)

M.D. Anderson Cancer Center - Recruiting N/A to 60 years.
- Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies.
Thiotepa; Clofarabine; Busulfan; Allogeneic Stem Cell Transplantation; Thymoglobulin (ATG); G-CSF (Filgrastim)

Small Lymphocytic Lymphoma, or Chronic Lymphocytic Leukemia Clinical Trial using ABT-199; Rituximab

AbbVie - Recruiting 18 years or older.
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
ABT-199; Rituximab

Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma Clinical Trial using Busulfan; Fludarabine

West Virginia University - Recruiting 18 years to 70 years.
- Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study.
Busulfan; Fludarabine

Multiple Myeloma, Myelodysplastic Syndrome, Hodgkin's Lymphoma, o Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects With Hematologic Malignancies.
MK-3475

DLBCL Clinical Trial

Rennes University Hospital - Recruiting 18 years to 65 years.
- Assessment of Biomarkers Initially Identified in Whole Blood by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans.

Hodgkin Lymphoma, or Metastatic Breast Cancer Clinical Trial

Rennes University Hospital - Recruiting 18 years to 75 years.
- BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology.

Non-Hodgkin's Lymphoma Clinical Trial using Carmustine; Etoposide; Cytarabine; Melphalan; Pegfilgrastim; 19-28z T CELLS; Autologous Stem Cell Transplantation

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma.
Carmustine; Etoposide; Cytarabine; Melphalan; Pegfilgrastim; 19-28z T CELLS; Autologous Stem Cell Transplantation

Head and Neck Cancers Clinical Trial using Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes.
Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I

Leukemia, Acute Lymphoblastic, Precursor B-Cell Lymphoblastic Leu Clinical Trial using Diagnosed as ALL

Asan Medical Center - Recruiting 15 years or older.
- Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center.
Diagnosed as ALL

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneou Clinical Trial using O6-benzylguanine; carmustine; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 19 years or older.
- Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma.
O6-benzylguanine; carmustine; laboratory biomarker analysis

Lymphoma, Non-Hodgkin Clinical Trial using Stem cell infusion; TLI; Anti-thymocyte globulin; Solumedrol; Tacrolimus; Mycophenolate mofetil

Washington University School of Medicine - Recruiting 18 years to 70 years.
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma.
Stem cell infusion; TLI; Anti-thymocyte globulin; Solumedrol; Tacrolimus; Mycophenolate mofetil

Cutaneous T-Cell Lymphoma Clinical Trial using Everolimus

Boston Medical Center - Recruiting 18 years or older.
- PHASE II TRIAL OF THE mTOR INHIBITOR EVEROLIMUS IN RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL).
Everolimus

Diffuse Large B Cell Lymphoma Clinical Trial using E7438

Eisai Inc. - Recruiting 18 years or older.
- An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas.
E7438

Mantle Cell Lymphoma Clinical Trial using Ibrutinib; Temsirolimus

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy.
Ibrutinib; Temsirolimus

Leukaemia, Lymphoblastic, Acute Clinical Trial using nelarabine

GlaxoSmithKline - Recruiting N/A to 21 years.
- A Multicentre, Single Arm, Observational Phase IV Study to Assess the Safety and Efficacy of Nelarabine in Children and Young Adults (up to 21 Years of Age) With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma.
nelarabine

Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplas Clinical Trial using Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Baylor College of Medicine - Recruiting N/A to 55 years.
- CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning.
Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Non Hodgkin's Lymphoma, NHL, Aggressive NHL, or Diffuse Large B-c Clinical Trial using Veltuzumab and 90Y-Epratuzumab Tetraxetan; 90Y-epratuzumab tetraxetan; veltuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- Phase I/II Study of Veltuzumab Combined With 90Y-Epratuzumab Tetraxetan in Patients With Relapsed/Refractory, Aggressive Non- Hodgkin's Lymphoma.
Veltuzumab and 90Y-Epratuzumab Tetraxetan; 90Y-epratuzumab tetraxetan; veltuzumab

Hodgkin Lymphoma Clinical Trial using Brentuximab vedotin (SGN-35); Doxorubicin HCL; Vinblastine Sulfate; Dacarbazine; Involved-Site Radiation Therapy (ISRT); Interim PET

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 60 years.
- A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy and 30 Gray Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma.
Brentuximab vedotin (SGN-35); Doxorubicin HCL; Vinblastine Sulfate; Dacarbazine; Involved-Site Radiation Therapy (ISRT); Interim PET

Hodgkin Lymphoma, or Diffuse Large B-Cell Lymphoma Clinical Trial using Cylcophosphamide; Etoposide; Alemtuzumab; Doxorubicin; Prednisone; Filgrastim; Rituximab; Vincristine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas.
Cylcophosphamide; Etoposide; Alemtuzumab; Doxorubicin; Prednisone; Filgrastim; Rituximab; Vincristine

AIDS-Related Primary Central Nervous System Lymphoma, or HIV Clinical Trial using Methotrexate; rituximab; antiviral therapy; leucovorin calcium

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy.
Methotrexate; rituximab; antiviral therapy; leucovorin calcium

Advanced Cancers, or Lymphoma Clinical Trial using NC-4016

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma.
NC-4016

B-cell Non Hodgkin Lymphoma, or Mature B-cell Leukemia Burkitt-ty Clinical Trial using Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C; Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 6 Months to 17 years.
- Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial.
Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C; Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C

Hodgkin Lymphoma, or Anaplastic Large Cell Lymphoma Clinical Trial using Adcetris; Bendamustine

Columbia University - Recruiting 18 years or older.
- A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma.
Adcetris; Bendamustine

Central Nervous System Lymphoma Clinical Trial using Methotrexate; Ara-C; Rituximab; Thiotepa; radiotherapy; BCNU; APBSCT

International Extranodal Lymphoma Study Group (IELSG) - Recruiting 18 years to 65 years.
- Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma.
Methotrexate; Ara-C; Rituximab; Thiotepa; radiotherapy; BCNU; APBSCT

Marginal Zone Lymphoma of Ocular Adnexal Clinical Trial using Doxycycline

International Extranodal Lymphoma Study Group (IELSG) - Recruiting 18 years or older.
- International Prospective Phase 2 Trial Addressing the Efficacy of First-line Chlamydophila Psittaci-eradicating Therapy With Protracted Administration of Doxycycline Followed by Eradication Monitoring and Antibiotic Re-treatment at Infection Re-occurrence in Patients With Newly Diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL).
Doxycycline

Mantle Cell Lymphoma Clinical Trial using Rituximab; bortezomib; Cladribine

Milton S. Hershey Medical Center - Recruiting 18 years or older.
- Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma: A Phase I/II Study (PSHCI 10-011).
Rituximab; bortezomib; Cladribine

Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma Clinical Trial using CAT-8015 (Moxetumomab Pasudotox)

MedImmune LLC - Recruiting 6 Months to 25 years.
- A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin's Lymphoma (NHL).
CAT-8015 (Moxetumomab Pasudotox)

Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma Clinical Trial using Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

University of Wisconsin, Madison - Recruiting 18 years or older.
- HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxanr) and Lenalidomide (Revlimidr) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Pos Clinical Trial using brentuximab vedotin

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas.
brentuximab vedotin

Leukemia Clinical Trial using Cyclophosphamide; Rituximab; Sapacitabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH.
Cyclophosphamide; Rituximab; Sapacitabine

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using anti-endosialin/TEM1 monoclonal antibody MORAb-004; pharmacological study; laboratory biomarker analysis

Morphotek - Recruiting 13 Months to 21 years.
- Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors.
anti-endosialin/TEM1 monoclonal antibody MORAb-004; pharmacological study; laboratory biomarker analysis

Mantle Cell Lymphoma Clinical Trial using R-CHOP; R-CHOP / R-HAD; Rituximab; Lenalidomide

The Lymphoma Academic Research Organisation - Recruiting 60 years or older.
- Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma.
R-CHOP; R-CHOP / R-HAD; Rituximab; Lenalidomide

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using iodine I 131 monoclonal antibody BC8; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Study Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies.
iodine I 131 monoclonal antibody BC8; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Colon Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Malign Clinical Trial using magnetic resonance imaging with positron emission tomography scanning

Case Comprehensive Cancer Center - Recruiting N/A or older.
- Evaluating Attenuation Correction Methods Applied to PET/MRI.
magnetic resonance imaging with positron emission tomography scanning

Non-Hodgkin's Lymphoma Clinical Trial using ibritumomab tiuxetan; BEAM chemotherapy and autologous stem-cell transplantation

Sheba Medical Center - Recruiting 18 years to 70 years.
- SPINOZA / ???????. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma.
ibritumomab tiuxetan; BEAM chemotherapy and autologous stem-cell transplantation

Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, or Renal Canc Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders.

Central Nervous System Lymphoma Clinical Trial using pemetrexed

Massachusetts General Hospital - Recruiting 18 years or older.
- A Phase I Study of the Treatment of Recurrent Primary or Secondary CNS Lymphoma With ALIMTA (Pemetrexed), a Novel Anti-Folate.
pemetrexed

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years.
- Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV.
leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Leukemia Lymphocytic Chronic B-Cell Clinical Trial using CC-292; Lenalidomide

Celgene Corporation - Recruiting 18 years or older.
- A Multicenter, Phase 1B, Open-Label Study to Determine the Safety and Activity of CC-292 in Combination With Lenalidomide in Subjects With Relapsed and /or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
CC-292; Lenalidomide

Lymphoma, Myeloma, or Leukemia Clinical Trial using Kappa CD28 T cells

Baylor College of Medicine - Recruiting 18 years or older.
- Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With Chronic Lymphocytic Leukemia, B-Cell Lymphoma or Multiple Myeloma.
Kappa CD28 T cells

B Cell Lymphoma, or Chronic Lymphocytic Leukemia Clinical Trial using CD19CAR-28-zeta T cells; Ipilimumab

Baylor College of Medicine - Recruiting N/A or older.
- Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia.
CD19CAR-28-zeta T cells; Ipilimumab

Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic My Clinical Trial using HSC835

Novartis - Recruiting 10 years to 55 years.
- A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies.
HSC835

Non-Hodgkin's Lymphoma Clinical Trial using Bendamustine + Rituximab + Pixantrone

Duke University - Recruiting 18 years or older.
- Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma.
Bendamustine + Rituximab + Pixantrone

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using alisertib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma.
alisertib; pharmacological study; laboratory biomarker analysis

Leukemia-Lymphoma, Adult T-Cell Clinical Trial using Bortezomib; Etoposide; Vincristine; Doxorubicin; Prednisone; Cyclophosphamide; Raltegravir

Washington University School of Medicine - Recruiting 18 years or older.
- Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma.
Bortezomib; Etoposide; Vincristine; Doxorubicin; Prednisone; Cyclophosphamide; Raltegravir

Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous S Clinical Trial using doxorubicin hydrochloride; cytarabine; daunorubicin hydrochloride; prednisone; pegaspargase; methotrexate; leucovorin calcium; cyclophosphamide; mercaptopurine; nelarabine; asparaginase; dexamethasone; thioguanine; vincristine sulfate; radiation therapy; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 1 year to 30 years.
- Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma.
doxorubicin hydrochloride; cytarabine; daunorubicin hydrochloride; prednisone; pegaspargase; methotrexate; leucovorin calcium; cyclophosphamide; mercaptopurine; nelarabine; asparaginase; dexamethasone; thioguanine; vincristine sulfate; radiation therapy; laboratory biomarker analysis

Diffuse Large B-Cell Lymphoma Clinical Trial using AEB071

Novartis - Recruiting 18 years or older.
- An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma.
AEB071

Solid Malignancy, or Lymphoma Clinical Trial using [18F] 4-L-Fluoroglutamine (2S,4R)

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years to 90 years.
- A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R).
[18F] 4-L-Fluoroglutamine (2S,4R)

Lymphoma Clinical Trial using alemtuzumab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate; flow cytometry; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study.
alemtuzumab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate; flow cytometry; pharmacological study

Hodgkin's Disease, or Non-Hodgkin's Lymphoma Clinical Trial using Vorinostat (SAHA) and Niacinamide; Vorinostat, Niacinamide and Etoposide

Columbia University - Recruiting 18 years or older.
- Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies.
Vorinostat (SAHA) and Niacinamide; Vorinostat, Niacinamide and Etoposide

Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Lymphoma Clinical Trial using Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG); Stem Cell Transplant; Stem Cells Collections; Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI); Fludarabine, Busulfan, and ATG

University of Chicago - Recruiting 1 year or older.
- Combined Haploidentical-Cord Blood Transplantation for Adults and Children.
Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG); Stem Cell Transplant; Stem Cells Collections; Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI); Fludarabine, Busulfan, and ATG

Brain and Central Nervous System Tumors, Chronic Myeloproliferati Clinical Trial using 3'-deoxy-3'-[18F]fluorothymidine

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET).
3'-deoxy-3'-[18F]fluorothymidine

Precursor Cell Lymphoblastic Leukemia-Lymphoma Clinical Trial using G-CSF; Ifosfamide; Etoposide; Dexamethasone; Mesna

Washington University School of Medicine - Recruiting 18 years or older.
- A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukemia.
G-CSF; Ifosfamide; Etoposide; Dexamethasone; Mesna

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using carfilzomib; laboratory biomarker analysis

University of Nebraska - Recruiting 19 years or older.
- Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma.
carfilzomib; laboratory biomarker analysis